Evidence map›Paper›PMID 42060164›Full record

ArticleJournal of neurology2026

Factors influencing accelerated progression in behavioral variant frontotemporal dementia.

Molly Split, Zachary J Kunicki, Daliah Ross, Rachel Keszycki, Sarah Prieto, Masood Manoochehri, Alyssa N De Vito, Brian Appleby, Chadwick M Hales, Chiadi Onyike and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Molly SplitDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA. molly_split@brown.edu.ORCID http://orcid.org/0000-0002-2342-0150
Zachary J KunickiDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Daliah RossDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Rachel KeszyckiMesulam Institute for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sarah PrietoDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Masood ManoochehriDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Alyssa N De VitoDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Brian ApplebyDepartment of Neurology, Case Western Reserve University, Cleveland, OH, USA.
Chadwick M HalesDepartment of Neurology, Center for Neurodegenerative Disease, Atlanta, GA, USA.
Chiadi OnyikeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA.
Corey T McMillanDepartment of Neurology and Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David ClarkDepartment of Neurology, Indiana University, Indianapolis, IN, USA.
David IrwinDepartment of Neurology and Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Douglas R GalaskoDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, USA.
Dylan WintCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Erik D RobersonDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Gabriel C LégerDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, USA.
Ging-Yuek Robin HsiungDivision of Neurology, University of British Columbia, Vancouver, BC, Canada.
Hilary W HeuerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Howard J RosenDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Ian M GrantDepartment of Neurology, Northwestern University Feinberg School, Chicago, IL, USA.
Ian R MackenzieDepartment of Pathology, University of British Columbia, Vancouver, BC, Canada.
Irene LitvanDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, USA.
John KornakDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Justin KwanNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Katya RascovskyDepartment of Neurology and Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kimiko Domoto-ReillyDepartment of Neurology, University of Washington, Seattle, WA, USA.
Lauren MassimoDepartment of Neurology and Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lawrence S HonigDepartment of Neurology, Gertrude H. Sergievsky Center, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Leah K ForsbergDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
M Carmela TartagliaDivision of Neurology, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Mario F MendezDepartment of Neurology, University of California, Los Angleles, Los Angeles, USA.
Neill Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Nupur GhoshalDepartments of Neurology and Psychiatry, Washington University School of Medicine, Washington University, St. Louis, MO, USA.
Peter LjubenkovDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
R Ryan DarbyDepartment of Neurology, Vanderbilt University, Nashville, TN, USA.
Sami BarmadaDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Sandra WeintraubDepartment of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, USA.
Suzee LeeDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
A Campbell SullivanGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, USA.
Adam BoxerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Adam M StaffaroniDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Allison SnyderNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Andrea BozokiDepartment of Neurology, University of North Carolina, Chapel Hill, NC, USA.
Belen PascualDepartment of Neurology, Houston Methodist, Houston, TX, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Bradley F BoeveDepartment of Neurology, Indiana University, Indianapolis, IN, USA.
Edward D HueyDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Megan BarkerDepartment of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA.

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
Genetic basis of neuropsychiatric symptoms in Alzheimer's diseaseU01AG079850 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gary Wayne Beecham, Edward D Huey · 2023 to 2026
$3.0M
NCATS NIH HHS U54 NS092089NIA NIH HHS U01 AG045390NIA NIH HHS U01 AG079850NIA NIH HHS U19 AG063911NIA NIH HHS U19: AG063911NINDS NIH HHS U01 AG045390NINDS NIH HHS U19: AG063911NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

introductionThis study aimed to identify neuropsychiatric, motor, and cognitive features associated with accelerated disease progression in behavioral variant frontotemporal dementia (bvFTD).

methods192 participants were classified as having mild or moderate disease severity based on CDR + NACC FTLD global scores, with scores of 0.5 or 1.0 defined as mild (n = 106) and 2.0 as moderate (n = 86). Participants were further categorized as having accelerated (mild: n = 35; moderate: n = 32) or non-accelerated (mild: n = 71; moderate: n = 54) progression rates based on change in CDR + NACC FTLD-SB sum of boxes (SB) scores (≥ 3.5 points) between Visit 1 and 2. Random forest modeling and logistic regression identified features most predictive of accelerated progression within each group.

resultsIn mild bvFTD, episodic memory impairment and presence of frontal-behavioral neuropsychiatric symptoms were predictive of accelerated progression, whereas in moderate bvFTD, language impairments and motor signs were the strongest predictors. Identified features improved prediction of accelerated progression beyond demographic and clinical factors in mild (∆R2 = .22, p < 0.001) and moderate bvFTD (∆R2 = 0.11, p = 0.08) but did not achieve statistical significance in the moderate group. DISCUSSION: Distinct clinical profiles predict accelerated progression in mild versus moderate bvFTD, underscoring the importance of stage-specific clinical markers for prognosis and care.

Indexed as

Disease ProgressionFrontotemporal DementiaAgedFemaleHumansMaleMiddle AgedNeuropsychological TestsSeverity of Illness IndexBvFTDCognitionMotorNeuropsychiatricProgression

Identifiers

PMID42060164
PMCPMC13273604

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.